Relações entre protocolos de tratamento para a leucemia linfoide aguda e efeitos neurocognitivos tardios
Combined efforts in the context of pediatric oncology towards establishing a balance between the increase of surviving rates and the reduction of cognitive deficits and behavioral troubles among ALL (acute lymphoblastic leukemia) survivors have been identified during the last years. The present r...
שמור ב:
| מחבר ראשי: | |
|---|---|
| מחברים אחרים: | |
| פורמט: | Dissertação |
| שפה: | pt_BR |
| יצא לאור: |
Brasil
|
| נושאים: | |
| גישה מקוונת: | https://repositorio.ufrn.br/jspui/handle/123456789/28889 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
| סיכום: | Combined efforts in the context of pediatric oncology towards establishing a balance between
the increase of surviving rates and the reduction of cognitive deficits and behavioral troubles
among ALL (acute lymphoblastic leukemia) survivors have been identified during the last
years. The present research effort aimed to investigate cognitive profiles of children and
teenagers ALL survivors, previously submitted to two distinct treatment protocols, GBTLI
LLA 1999 and BFM 2002. Two other independent variables were considered - the ages of
participants when diagnosed and the amount of time after treatment. Treatment protocols
differ essentially due to Methotrexate (MTX) dosage; this drug is the main agent in
preventing central nervous system cells infiltration. Thirty-one children having finalized ALL
treatment have participated in the present research; ages varied from six to twelve years, and
all participants were under medical supervision by public community reference oncology
services from the Brazilian state of Rio Grande do Norte. Two groups of subjects were
constituted, taking into account treatment protocols and the other independent variables
mentioned above. Neuropsychological evaluation covered the following cognitive abilities:
intellectual capacity, executive functions, attention, visuospatial processing and visuoconstruction. Data were categorized and analyzed with the support of statistical descriptive
(uni and multidimensional cluster analysis) and inferential (Pearson Qui2) tools. Results
showed that participants submitted to bigger MTX dosage, age level under five years at
diagnosis and out of treatment for two or more years are more liable to develop cognitive
deficits that could be associated to ALL and its medical treatment. |
|---|